With today's news that they are tripling insulin production for Afrezza, one can only guess that the launch is at or ahead of plan. Granted, we are only to weeks into the launch, but this is a very good sign.
The physicians have been cautiously receptive. Exhubera did us no favors, but once they see the myriad of differences, they are far more interested. I sense this will be very well-received as we move forward. Afrezza really is a better mousetrap.
